Abstract:Background Our previous studies revealed a critical role of a novel CTLA4-protein kinase C-eta (PKCη) signaling axis in mediating the suppressive activity of regulatory T cells (Tregs) in antitumor immunity. These studies have employed adoptive transfer of germline PKCη-deficient ( Prkch −/− ) Tregs into Prkch +/+ mice prior to tumor implantation. Here, we extended these findings into a biologically and clinically more relevant context. Methods We have analyzed the role of PKCη in antitumor immunity and the tumor microenvironment (TME) in intact tumor-bearing mice with Treg-specific or CD8 + T cell-specific Prkch deletion, including in a therapeutic model of combinatorial treatment. In addition to measuring tumor growth, we analyzed the phenotype and functional attributes of tumor-infiltrating immune cells, particularly Tregs and dendritic cells (DCs). Results Using two models of mouse transplantable cancer and a genetically engineered autochthonous hepatocellular carcinoma (HCC) model, we found, first, that mice with Treg-specific Prkch deletion displayed a significantly reduced growth of B16–F10 melanoma and TRAMP-C1 adenocarcinoma tumors. Tumor growth reduction was associated with a less immunosuppressive TME, indicated by increased numbers and function of tumor-infiltrating CD8 + effector T cells and elevated expression of the costimulatory ligand CD86 on intratumoral DCs. In contrast, CD8 + T cell-specific Prkch deletion had no effect on tumor growth or the abundance and functionality of CD8 + effector T cells, consistent with findings that Prkch −/− CD8 + T cells proliferated normally in response to in vitro polyclonal or specific antigen stimulation. Similar beneficial antitumor effects were found in mice with germline or Treg-specific Prkch deletion that were induced to develop an autochthonous HCC. Lastly, using a therapeutic model, we found that monotherapies consisting of Treg-specific Prkch deletion or vaccination with irradiated Fms-like tyrosine kinase 3 ligand (Flt3L)-expressing B16–F10 tumor cells post-tumor implantation significantly delayed tumor growth. This effect was more pronounced in mice receiving a combination of the two immunotherapies. Conclusion These findings demonstrate the potential utility of PKCη inhibition as a viable clinical approach to treat patients with cancer, especially when combined with adjuvant therapies.

PPARd restricts intratumoral Treg function through negatively regulating the CIITA-MHCII axis

PPARδ restrains the suppression function of intra-tumoral Tregs by limiting CIITA-MHC II expression

Abstract 6858: PPARδ and type 1 interferon collaboratively regulate CIITA-MHCII pathway: Unveiling novel mechanisms of tumor Tregs

Cancer Immunotherapies Targeting Tumor-Associated Regulatory T Cells

PPARδ inhibition blocks the induction and function of tumor-induced IL-10 + regulatory B cells and enhances cancer immunotherapy

Regulatory T cells in cancer immunosuppression — implications for anticancer therapy

Peripheral-derived regulatory T cells contribute to tumor-mediated immune suppression in a nonredundant manner

Lipid metabolism in tumor-infiltrating regulatory T cells: perspective to precision immunotherapy

The role of the programmed cell death protein-1/programmed death-ligand 1 pathway, regulatory T cells and T helper 17 cells in tumor immunity: a narrative review

Dendritic cell-intrinsic PTPN22 negatively regulates antitumor immunity and impacts anti-PD-L1 efficacy

Depletion of Regulatory T Cells Facilitates Growth of Established Tumors: A Mechanism Involving the Regulation of Myeloid-Derived Suppressor Cells by Lipoxin A4

Precise Spatiotemporal Interruption of Regulatory T-cell-Mediated CD8(+) T-cell Suppression Leads to Tumor Immunity

Leveraging the Treg-intrinsic CTLA4–PKCη signaling pathway for cancer immunotherapy

Targeting tumor-infiltrating tregs for improved antitumor responses

Hypoxia-reprogrammed regulatory group 2 innate lymphoid cells promote immunosuppression in pancreatic cancer

Program Death-1 Regulates Peripheral T Cell Tolerance Via an Anergy-Independent Mechanism

PTIR1 acts as an isoform of DDX58 and promotes tumor immune resistance through activation of UCHL5

Potentiating CD8+ T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling

Control of regulatory T (Treg) cell function by protein kinase C-eta (PKCη): A novel target for cancer immunotherapy

Antibody-based Cancer Immunotherapy by Targeting Regulatory T Cells

Regulatory B cells induced by pancreatic cancer cell-derived interleukin-18 promote immune tolerance via the PD-1/PD-L1 pathway